Corbus Pharmaceuticals Holdings, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $1.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-08-06
- Corbus Pharmaceuticals Holdings, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2017-12-31 was $157.34K, a 60.04% decline year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2017-09-30 was $6.13K, a 97.59% decline year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2017-06-30 was $527.34K.
- Corbus Pharmaceuticals Holdings, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2017-03-31 was $1.40M.
- Corbus Pharmaceuticals Holdings, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2017 was $2.09M, a 108.40% increase from fiscal 2016.
- Corbus Pharmaceuticals Holdings, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2016 was $1.00M, a 558.44% increase from fiscal 2015.
- Corbus Pharmaceuticals Holdings, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2015 was $152.53K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.00K 10-Q · filed 2026-08-06 | |||
| 2019-09-30 | $324.57K 10-Q · filed 2019-11-07 | |||
| 2018-09-30 | $494.36K 10-Q · filed 2019-11-07 | |||
| 2017-12-31 | $157.34K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $163.47K derived: sum of 2 quarters · filed 2018-03-12 | $690.80K derived: sum of 3 quarters · filed 2018-03-12 | $2.09M 10-K · filed 2018-03-12 |
| 2017-09-30 | $6.13K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $533.46K derived: sum of 2 quarters · filed 2017-11-08 | $1.94M 10-Q · filed 2017-11-08 | $2.33M derived: sum of 4 quarters · filed 2018-03-12 |
| 2017-06-30 | $527.34K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $1.93M 10-Q · filed 2017-08-09 | $2.32M derived: sum of 3 quarters · filed 2018-03-12 | $2.58M derived: sum of 4 quarters · filed 2018-03-12 |
| 2017-03-31 | $1.40M 10-Q · filed 2017-05-09 | $1.80M derived: sum of 2 quarters · filed 2018-03-12 | $2.05M derived: sum of 3 quarters · filed 2018-03-12 | |
| 2016-12-31 | $393.71K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $647.92K derived: sum of 2 quarters · filed 2018-03-12 | $1.00M 10-K · filed 2018-03-12 | |
| 2016-09-30 | $254.21K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $610.61K 10-Q · filed 2017-11-08 | ||
| 2016-06-30 | $356.40K 10-Q · filed 2017-08-09 | |||
| 2015-12-31 | $57.42K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $49.87K derived: sum of 2 quarters · filed 2018-03-12 | $152.53K 10-K · filed 2018-03-12 | |
| 2015-09-30 | -$7.56K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | $95.11K 10-Q · filed 2016-11-10 | ||
| 2015-06-30 | $102.66K 10-Q · filed 2016-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |